CG Oncology (CGON) is in the spotlight after several analysts, including Guggenheim, initiated coverage. This attention is supported by promising late-stage trial results for its lead bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback